Cephaloridine. II. The effect of cephaloridine on experimental model infections.
D000818:Animals; D002509:Cephaloridine / Q000008:administration & dosage / Q000627:therapeutic use*; D002701:Chloramphenicol / Q000627:therapeutic use; D003023:Cloxacillin / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D006168:Guinea Pigs; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000627:therapeutic use; D008712:Methicillin / Q000627:therapeutic use; D051379:Mice; D008954:Models, Biological; D009254:Nafcillin / Q000627:therapeutic use; D010068:Oxacillin / Q000627:therapeutic use; D011512:Proteus Infections / Q000188:drug therapy*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000627:therapeutic use
D009254:Nafcillin; D007612:Kanamycin; D004917:Erythromycin; D002701:Chloramphenicol; D014640:Vancomycin; D002509:Cephaloridine; D003023:Cloxacillin; D008712:Methicillin; D010068:Oxacillin